{"id":"W3195751328","doi":"10.1136/jitc-2021-002973","title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institutes of Health; National Center for Advancing Translational Sciences; AstraZeneca; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Durvalumab; Tremelimumab; Medicine; Lung cancer; PD-L1; Internal medicine; Oncology; Squamous cell cancer; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007498133,0.0007603263,0.001878989,0.000377055,0.0006617508,0.00008548045,0.0004457029,0.0002307452,0.001150647],"category_scores_gemma":[0.00003825071,0.0005646406,0.0008466098,0.0007054278,0.0001894457,0.0002994328,0.00003653026,0.0004281632,3.520346e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001148143,"about_ca_system_score_gemma":0.002324832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001808792,"about_ca_topic_score_gemma":0.0008136824,"domain_scores_codex":[0.9950354,0.0002266205,0.001872548,0.0007496185,0.001238643,0.0008771305],"domain_scores_gemma":[0.9945464,0.0002403029,0.001865727,0.0008848711,0.002243899,0.0002188737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5794823,0.03741722,0.08091275,0.001759322,0.01177649,0.00008401699,0.0184681,0.0003196307,0.2141967,0.000007537361,0.004895318,0.05068064],"study_design_scores_gemma":[0.6131319,0.1251394,0.06576171,0.002131879,0.003021585,0.00003498203,0.005752743,0.0005245071,0.1308381,0.00001985292,0.05202151,0.001621831],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9142769,0.07697067,0.0001151881,0.0003454409,0.0009489424,0.006645485,0.0005954667,0.00004549669,0.00005638174],"genre_scores_gemma":[0.978761,0.01417892,0.000239404,0.0004028797,0.0002702123,0.0009655195,0.00009364951,0.0002458221,0.004842628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08772217,"threshold_uncertainty_score":0.9997624,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01685992661131969,"score_gpt":0.3365914877365322,"score_spread":0.3197315611252125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}